Withaferin-A reduces type I collagen expression in vitro and inhibits development of myocardial fibrosis in vivo - sprookjes - yvandenbroek - TriplyDB

Withaferin-A reduces type I collagen expression in vitro and inhibits development of myocardial fibrosis in vivo

Withaferin-A reduces type I collagen expression in vitro and inhibits development of myocardial fibrosis in vivo

http://www.wikidata.org/entity/Q28482173

about

RNA protein interactions governing expression of the most abundant protein in human body, type I collagen Use of dietary phytochemicals to target inflammation, fibrosis, proliferation, and angiogenesis in uterine tissues: promising options for prevention and treatment of uterine fibroids?Withaferin A effectively targets soluble vimentin in the glaucoma filtration surgical model of fibrosis.Pharmacoproteomic analysis reveals that metapristone (RU486 metabolite) intervenes E-cadherin and vimentin to realize cancer metastasis chemoprevention Serine-threonine kinase receptor-associated protein (STRAP) regulates translation of type I collagen mRNAs.Identify potential drugs for cardiovascular diseases caused by stress-induced genes in vascular smooth muscle cells.Heart regeneration with engineered myocardial tissue Posttranslational modifications of lysine and evolving role in heart pathologies-recent developments.1,4-Butanediol diglycidyl ether-cross-linked hyaluronan inhibits fibrosis in rat primary tenocytes by down-regulating autophagy modulation.Annexin A2 contributes to lung injury and fibrosis by augmenting factor Xa fibrogenic activity.Vimentin is a component of a complex that binds to the 5'-UTR of human heme-regulated eIF2α kinase mRNA and regulates its translation.Characterization of binding of LARP6 to the 5' stem-loop of collagen mRNAs: implications for synthesis of type I collagen Withaferin A induces Nrf2-dependent protection against liver injury: Role of Keap1-independent mechanisms.Clinical significance of interleukin‑6 and inducible nitric oxide synthase in ketamine‑induced cystitis.Clinical implications of nonsarcomeric gene polymorphisms in hypertrophic cardiomyopathy.An Adaptogen: Withaferin A Ameliorates in Vitro and in Vivo Pulmonary Fibrosis by Modulating the Interplay of Fibrotic, Matricelluar Proteins, and Cytokines.Withaferin A Suppresses Beta Amyloid in APP Expressing Cells: Studies for Tat and Cocaine Associated Neurological Dysfunctions

P2860

Q26827684-F3908540-971D-4320-99F7-F847CF6D96A8 Q34125151-B3DBA510-0DDD-46DA-A1AA-EBE52EF2E4F9 Q34718470-C136D05D-38E7-458E-ABBF-BD2750ABD081 Q36638387-E0E3DE7F-2598-451F-92D4-542C9F2C27B7 Q37264955-D08316C9-19D1-4650-913F-1F4DAEF78EFD Q37302839-C9378E3B-F026-40B8-8AB6-3B96E40FE8C1 Q38211168-9D5F0283-05C4-491B-84F1-941E621C9634 Q38272115-0E94C957-F243-4272-AA18-FAB97FA9B87B Q38896422-93E1648B-3439-4C1C-A4EA-9B5E876D3469 Q38914096-04DCFB16-6196-4506-A435-BF529CC89921 Q39203220-D9DFA2C6-610E-4544-86E5-8E106EBBCDCE Q41404805-E026F9E1-EE4F-45BF-AD34-E80789B6C0E1 Q47260584-649F4189-236D-4B07-9A1F-FFF13B41EF8E Q49257594-5D2046ED-AC9F-4D55-B40B-5E20FE2466BA Q53269159-8BC3B983-E7B8-4343-8941-DDA5B3F27969 Q55073347-3057B624-B672-4205-B4B7-AC9A572B3DAC Q57821144-316A5D75-FD05-4299-9FA3-0AF9D08FE1D6

P2860

Withaferin-A reduces type I collagen expression in vitro and inhibits development of myocardial fibrosis in vivo

http://www.wikidata.org/entity/Q28482173

description

2012 nî lūn-bûn

@nan

2012 թուականին հրատարակուած գիտական յօդուած

@hyw

2012 թվականին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Withaferin-A reduces type I co ...... of myocardial fibrosis in vivo

@ast

Withaferin-A reduces type I co ...... of myocardial fibrosis in vivo

@en

Withaferin-A reduces type I co ...... of myocardial fibrosis in vivo

@nl

type

label

Withaferin-A reduces type I co ...... of myocardial fibrosis in vivo

@ast

Withaferin-A reduces type I co ...... of myocardial fibrosis in vivo

@en

Withaferin-A reduces type I co ...... of myocardial fibrosis in vivo

@nl

prefLabel

Withaferin-A reduces type I co ...... of myocardial fibrosis in vivo

@ast

Withaferin-A reduces type I co ...... of myocardial fibrosis in vivo

@en

Withaferin-A reduces type I co ...... of myocardial fibrosis in vivo

@nl

P1433

Q28482173-72E31910-B024-47F0-8203-DA6539A9FF4F

P1476

Q28482173-B29CA07C-ABC7-4D03-AFAC-22F11062FE87

P2093

Q28482173-071AACA8-10A9-4FFD-8A11-DC2D50512A52

Q28482173-51981FA4-F270-4E74-81E4-FB4F0690CD89

Q28482173-95A119A2-8AF2-40E6-9618-EC64257375DD

Q28482173-EC26B026-AF36-461A-8FE8-4440E154D99E

P2860

Q28482173-1554FBB6-4179-40DF-9B9B-D45E2DBF751B

Q28482173-1F5FF4B5-BAC0-4603-B5CD-E50FCAC703E6

Q28482173-1FEAB028-A732-406E-A9E0-5EDD9C0C2A4E

Q28482173-2E218F92-E3C8-4AA1-A667-F3E1A272A40F

Q28482173-35F36446-9D09-445F-B9E8-4448FA8FFA24

Q28482173-3E379C8A-4BD5-4F54-ACA1-A83D916878AA

Q28482173-3F249216-05ED-49D6-8D7F-7FB66EB36A65

Q28482173-3FCAD65A-D647-4143-B8E6-18F3ECD2838F

Q28482173-405CC68F-5E2C-4493-B02C-49A6F766A47D

Q28482173-4266D79A-9930-402D-90FB-4FF701A7E119

P304

Q28482173-E829E776-9FC2-4B54-8BD9-76CF10729507

P31

Q28482173-3A162160-3AF7-4D6C-A107-730A56BF6020

P3181

Q28482173-81556825-6624-4E9A-B800-911A657CEB93

P356

Q28482173-F3236219-9A80-4675-B283-34CE75E91FFB

P407

Q28482173-0D6A567C-C0FA-407A-B9F3-85A039DB7A6D

P433

Q28482173-02E151A1-8D16-4B03-90AC-F2ABB6664336

P478

Q28482173-FFA6E03C-FE3F-403E-B0C7-6815D51466D5

P577

Q28482173-064665AA-4743-4A0D-A7C5-C6114E1DE620

P5875

Q28482173-EC477CAF-F269-4211-AAC7-729C6FC223CE

P698

Q28482173-7D19F6DE-7D1F-42D9-BFA0-66B80EDEE08E

P932

Q28482173-6E0CE1D8-C6AE-46CE-95AF-1FBDD187EB8D

P3181

P356

JOURNAL.PONE.0042989

P1433

P1476

Withaferin-A reduces type I co ...... of myocardial fibrosis in vivo

@en

P2093

Azariyas A Challa

http://www.w3.org/2001/XMLSchema#string

Branko Stefanovic

http://www.w3.org/2001/XMLSchema#string

John Blackmon

http://www.w3.org/2001/XMLSchema#string

Milica Vukmirovic

http://www.w3.org/2001/XMLSchema#string

P2860

The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin

Binding of LARP6 to the conserved 5' stem-loop regulates translation of mRNAs encoding type I collagen

Cellular and molecular mechanisms of fibrosis

Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene.

SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1

Transforming growth factor beta increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability.

Withaferin A targets intermediate filaments glial fibrillary acidic protein and vimentin in a model of retinal gliosis

Inhibition of the NEMO/IKKβ association complex formation, a novel mechanism associated with the NF-κB activation suppression by Withania somnifera's key metabolite withaferin A.

New aspects of hepatic fibrosis.

Increased expression of cytoskeletal, linkage, and extracellular proteins in failing human myocardium.

P304

e42989

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3295146

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0042989

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230686482

http://www.w3.org/2001/XMLSchema#string

P698

22900077

http://www.w3.org/2001/XMLSchema#string

P932

3416765

http://www.w3.org/2001/XMLSchema#string